search
Back to results

US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism

Primary Purpose

Pulmonary Embolism

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Adient absorbable filter + best practice VTE prophylaxis
best practice VTE prophylaxis
Sponsored by
Adient Medical
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pulmonary Embolism focused on measuring Vena Cava Filters, Embolic Protection Devices

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Aged 18 years or older
  • Willing to comply with the specified follow-up requirements including contrast enhanced CTs for the 9-month duration of the study
  • For female subjects of childbearing potential: a negative pregnancy test within 48 hours prior to the implantation procedure
  • For the prophylactic cohort, high risk VTE denoted by either:

Caprini score > 8 for surgical ICU, Parvizi score ≥ 150 for TKA (total knee replacement), ISS score ≥ 24 for trauma.

  • For the therapeutic cohort, documented VTE per the following:

Pulmonary thromboembolism when anticoagulants are contraindicated, Failure of anticoagulant therapy in thromboembolic diseases, Emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced.

  • Requirement of temporary PE protection (8 weeks) based on clinical judgment
  • Fully informed subject or caretaker consent having executed an Institutional Review Board (IRB) or approved informed consent.

Exclusion Criteria:

  • Expected high VTE risk to extend beyond 8 weeks
  • Vena cava filter currently implanted
  • History of abdominal or pelvic radiation therapy
  • Previous IVC filter placement/retrieval within 6 months prior to randomization
  • Confirmed positive blood cultures within the last 48 hours if there is bacteremia
  • Known sensitivity to radiographic contrast medium that cannot be adequately prophylactically pre-medicated
  • Known allergy or intolerance to IVC filter materials (i.e. PDSII absorbable suture)
  • Pregnant, lactating, or plans to become pregnant during investigation follow-up period
  • Renal insufficiency (GFR < 60) or requiring renal replacement therapy
  • IVC effective diameter (D) <16 mm or >28 mm anywhere within L1-L4, D = √(AP*Lat)
  • Less than 7cm from inferior-most renal vein to the iliac vein confluence
  • Duplication of the IVC
  • Any thrombus or occlusion in IVC on pre-procedural CT cavogram
  • Life expectancy of < 12 months

Sites / Locations

  • University of Colorado Anschutz Medical Campus
  • IU Health University Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Therapeutic

Prophylactic - Test

Prophylactic - Control

Arm Description

The therapeutic arm will include subjects with diagnosed symptomatic VTE (PE and/or DVT). Each subject will receive an Adient absorbable filter to help prevent a subsequent PE. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.

The Prophylactic - Test arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive an Adient absorbable filter to help prevent PE in addition to being administered current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.

The Prophylactic - Control arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit.

Outcomes

Primary Outcome Measures

Primary Effectiveness Endpoint - Prophylactic Cohort: incidence of new clinically significant PE
Clinically significant PE includes asymptomatic proximal PE screened at 2 weeks, in addition to symptomatic PE through 8 weeks post index event confirmed by computed tomography (CT) angiography. Proximal PE includes thrombus (blood clots) observed in the pulmonary trunk, main pulmonary arteries, or lobar arteries.
Primary Composite Safety Endpoint - Prophylactic Cohort: incidence of absorbable filter deployment without complications
Potential complications include: (a) caval thrombotic occlusion within 9 months, (b) all-filter embolization within 9 months, (c) serious filter-related complications within 9 months, (d) filter placement procedural related Series Adverse Events (SAE) within the perioperative period (96 hours), (e) filter placement vascular access site SAE within the perioperative period, (f) symptomatic PE subsequent to filter deployment within 9 months.
Primary DVT Safety Endpoint - Prophylactic Cohort: incidence of all DVT post index event
All DVT includes both symptomatic DVT and asymptomatic DVT screened at 2 weeks, 10 weeks and 9 months.
Primary Composite Safety and Effectiveness Endpoint - Therapeutic Cohort: composite rate of technical filter placement success without complications
Potential complications include (a) new symptomatic PE through 8 weeks, (b) filter migration (> 2cm), (c) filter embolization, (d) caval perforation (> 5mm), (e) symptomatic caval thrombosis, and (f) any other symptomatic filter-related complication requiring invasive intervention, or filter related death.

Secondary Outcome Measures

Incidence of new symptomatic PE through 8 weeks confirmed by CT angiography
Miller Score for symptomatic and asymptomatic PE
Quantification of the occlusion of the pulmonary vascular bed from a PE.
Incidence of caval occlusion / thrombosis confirmed by CT cavogram
Incidence of IVC caval stenosis and occlusion confirmed by CT cavogram
Incidence of common femoral and iliac venous thrombosis ipsilateral to filter insertion site
Detected on ultrasound.
Incidence of DVT
Detected on ultrasound.
Incidence of major procedure-related or device-related adverse events
Incidence of major bleeding
Major bleeding defined by International Society on Thrombosis and Haemostases.

Full Information

First Posted
November 9, 2021
Last Updated
August 29, 2023
Sponsor
Adient Medical
Collaborators
Avania, ICON plc
search

1. Study Identification

Unique Protocol Identification Number
NCT05127915
Brief Title
US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism
Official Title
A Prospective, Multicenter, Pivotal Study With Randomized Controlled Prophylactic and Independent Therapeutic Cohorts to Evaluate the Safety and Efficacy of an Absorbable Vena Cava Filter for Pulmonary Embolism Prevention
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 27, 2023 (Actual)
Primary Completion Date
May 31, 2026 (Anticipated)
Study Completion Date
December 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Adient Medical
Collaborators
Avania, ICON plc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The objective of the study is to evaluate the safety and efficacy of the Adient absorbable filter for the prevention of pulmonary embolism (PE: blood clot in the lungs). PE claims the lives of over 100,000 Americans each year, more than breast cancer, traffic fatalities and HIV combined. Pharmaceutical anticoagulation (blood thinners) that reduce blood clot formation represent the standard of care for treating patients at risk for PE. However, for people who are temporarily unable to use anticoagulants, such as those who have suffered major trauma or those who are scheduled for surgical procedures, inferior vena cava (IVC) filters are used to help protect against PE. These blood filters prevent large blood clots that originate in the deep veins of the legs (deep vein thrombosis (DVT)) from reaching your lungs causing a potentially life-threatening PE. Conventional metal IVC filters have been proven effective at reducing the incidence of PE, however, most require retrieval. If not retrieved within a timely manner (months), they can perforate the IVC, impale nearby organs with their barbed struts, and cause blood clots. In contrast, the Adient absorbable filter traps blood clots similar to conventional metal IVC filters, but following the 8 week protection period, the filter itself breaks down into carbon dioxide and water. Hence no filter retrieval is required and complications are less likely due to the shortened indwell time. Once blood clots are trapped in the absorbable filter, the body's thrombolytic enzymes dissolve the clots within weeks while the filter itself resorbs in 6 to 8 months. The absorbable filter is braided from absorbable suture that has been proven safe over 4 decades. The question being addressed with the randomized controlled trial portion is whether the placement of the absorbable filter in addition to current best practice PE prevention (sequential compression machines, compression stockings, and anticoagulants when indicated) significantly reduces the incidence of clinically significant PE in high risk subjects. The absorbable filter will be indicated for the temporary prevention of PE in patients with transient high risk for venous thromboembolism (DVT and/or PE) with or without venous thromboembolic disease and as an enhancement to pharmaceutical anticoagulation and mechanical prophylaxis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pulmonary Embolism
Keywords
Vena Cava Filters, Embolic Protection Devices

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Masking Description
Data will be reviewed by the Outcomes Assessor for futility at 25% and 50% enrollment. Subsequently at 75% enrollment, the Outcomes Assessor will conduct an interim assessment for potentially stopping the study with overwhelming efficacy of the filter cohort.
Allocation
Randomized
Enrollment
854 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Therapeutic
Arm Type
Experimental
Arm Description
The therapeutic arm will include subjects with diagnosed symptomatic VTE (PE and/or DVT). Each subject will receive an Adient absorbable filter to help prevent a subsequent PE. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.
Arm Title
Prophylactic - Test
Arm Type
Experimental
Arm Description
The Prophylactic - Test arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive an Adient absorbable filter to help prevent PE in addition to being administered current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit to perform safety and filter status evaluations.
Arm Title
Prophylactic - Control
Arm Type
Active Comparator
Arm Description
The Prophylactic - Control arm will include subjects who are at transient high risk for PE and do not have diagnosed symptomatic VTE (PE and/or DVT). If randomized into this prophylactic arm, study subjects will receive current best practice PE prevention, namely sequential compression machines, compression stockings, and anticoagulants when indicated. All study subjects will return to the investigation site for the Follow-up Visits at Week 2 (±3 days), Week 10 (±1 week) and Month 9 (±2 weeks). Subjects will be interviewed and examined at each follow-up visit.
Intervention Type
Device
Intervention Name(s)
Adient absorbable filter + best practice VTE prophylaxis
Intervention Description
Adient absorbable filter helps prevent PE during an 8 week protection period then gradually breaks down into carbon dioxide and water within 6 to 8 months. The absorbable filter does not require removal.
Intervention Type
Device
Intervention Name(s)
best practice VTE prophylaxis
Intervention Description
Best practice VTE prophylaxis includes sequential compression machines, compression stockings, and anticoagulants (blood thinners) when indicated.
Primary Outcome Measure Information:
Title
Primary Effectiveness Endpoint - Prophylactic Cohort: incidence of new clinically significant PE
Description
Clinically significant PE includes asymptomatic proximal PE screened at 2 weeks, in addition to symptomatic PE through 8 weeks post index event confirmed by computed tomography (CT) angiography. Proximal PE includes thrombus (blood clots) observed in the pulmonary trunk, main pulmonary arteries, or lobar arteries.
Time Frame
2 weeks for asymptomatic proximal PE screening and through 8 weeks for symptomatic PE
Title
Primary Composite Safety Endpoint - Prophylactic Cohort: incidence of absorbable filter deployment without complications
Description
Potential complications include: (a) caval thrombotic occlusion within 9 months, (b) all-filter embolization within 9 months, (c) serious filter-related complications within 9 months, (d) filter placement procedural related Series Adverse Events (SAE) within the perioperative period (96 hours), (e) filter placement vascular access site SAE within the perioperative period, (f) symptomatic PE subsequent to filter deployment within 9 months.
Time Frame
96 hours to 9 months depending on the safety parameter
Title
Primary DVT Safety Endpoint - Prophylactic Cohort: incidence of all DVT post index event
Description
All DVT includes both symptomatic DVT and asymptomatic DVT screened at 2 weeks, 10 weeks and 9 months.
Time Frame
9 months overall duration
Title
Primary Composite Safety and Effectiveness Endpoint - Therapeutic Cohort: composite rate of technical filter placement success without complications
Description
Potential complications include (a) new symptomatic PE through 8 weeks, (b) filter migration (> 2cm), (c) filter embolization, (d) caval perforation (> 5mm), (e) symptomatic caval thrombosis, and (f) any other symptomatic filter-related complication requiring invasive intervention, or filter related death.
Time Frame
9 months
Secondary Outcome Measure Information:
Title
Incidence of new symptomatic PE through 8 weeks confirmed by CT angiography
Time Frame
8 weeks
Title
Miller Score for symptomatic and asymptomatic PE
Description
Quantification of the occlusion of the pulmonary vascular bed from a PE.
Time Frame
9 months
Title
Incidence of caval occlusion / thrombosis confirmed by CT cavogram
Time Frame
10 weeks
Title
Incidence of IVC caval stenosis and occlusion confirmed by CT cavogram
Time Frame
9 months
Title
Incidence of common femoral and iliac venous thrombosis ipsilateral to filter insertion site
Description
Detected on ultrasound.
Time Frame
2 weeks, 10 weeks, and 9 months
Title
Incidence of DVT
Description
Detected on ultrasound.
Time Frame
2 weeks, 10 weeks, and 9 months
Title
Incidence of major procedure-related or device-related adverse events
Time Frame
9 months
Title
Incidence of major bleeding
Description
Major bleeding defined by International Society on Thrombosis and Haemostases.
Time Frame
9 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
INCLUSION CRITERIA: Aged 18 years or older Willing to comply with the specified follow-up requirements including contrast enhanced CTs for the 9-month duration of the study For female subjects of childbearing potential: a negative pregnancy test within 48 hours prior to the implantation procedure For the prophylactic cohort, high risk VTE denoted by either: Caprini score > 8 for surgical ICU, Parvizi score ≥ 150 for TKA (total knee replacement), ISS score ≥ 24 for trauma. For the therapeutic cohort, documented VTE per the following: Pulmonary thromboembolism when anticoagulants are contraindicated, Failure of anticoagulant therapy in thromboembolic diseases, Emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced. Requirement of temporary PE protection (8 weeks) based on clinical judgment Fully informed subject or caretaker consent having executed an Institutional Review Board (IRB) or approved informed consent. EXCLUSION CRITERIA: Expected high VTE risk to extend beyond 8 weeks. Vena cava filter currently implanted History of abdominal or pelvic radiation therapy Previous IVC filter placement/retrieval within 6 months prior to randomization Confirmed positive blood cultures within the last 48 hours if there is bacteremia Known sensitivity to radiographic contrast medium that cannot be adequately prophylactically pre-medicated Known allergy or intolerance to IVC filter materials (i.e. PDSII absorbable suture) Pregnant, lactating, or plans to become pregnant during investigation follow-up period Renal insufficiency (GFR < 60) or requiring renal replacement therapy IVC effective diameter (D) <16 mm or >28 mm anywhere within L1-L4, D = √(AP*Lat) Less than 7cm from inferior-most renal vein to the iliac vein confluence Duplication of the IVC Any thrombus or occlusion in IVC on pre-procedural CT cavogram Life expectancy of < 12 months Simultaneous participation in another investigative drug or device trial that has not reached its primary endpoint Other co-morbid condition that, in the opinion of the Investigator, could limit the subject's ability to participate in or would affect the scientific integrity of the study Previously enrolled in a clinical investigation of the Adient filter. For Roll In, patient has advanced heart failure or recent (6 weeks) myocardial infarction. - - - Advanced heart failure is defined by NYHA class IV or AHA/ACC/HFSA stage D or LVEF < 40%. Subjects with MI diagnosed with ECG alone without MI history and symptoms are not excluded.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Matthew Johnson, MD
Organizational Affiliation
Indiana University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Colorado Anschutz Medical Campus
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
IU Health University Hospital
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33008719
Citation
Elizondo G, Eggers M, Falcon M, Trevino M, Marrufo R, Perez C, Nunez E, Moreno R, Mitchell A, Sheppard A, Dria S, Jay T, Kirk R, Hovsepian D, Steele J. First-in-Human Study with Eight Patients Using an Absorbable Vena Cava Filter for the Prevention of Pulmonary Embolism. J Vasc Interv Radiol. 2020 Nov;31(11):1817-1824. doi: 10.1016/j.jvir.2020.07.021. Epub 2020 Sep 29.
Results Reference
background
PubMed Identifier
31202677
Citation
Eggers M, Rousselle S, Urtz M, Albright R, Will A, Jourden B, Godshalk C, Dria S, Huang S, Steele J. Randomized Controlled Study of an Absorbable Vena Cava Filter in a Porcine Model. J Vasc Interv Radiol. 2019 Sep;30(9):1487-1494.e4. doi: 10.1016/j.jvir.2019.03.010. Epub 2019 Jun 13.
Results Reference
background
PubMed Identifier
28708470
Citation
Huang SY, Eggers M, McArthur MJ, Dixon KA, McWatters A, Dria S, Hill LR, Melancon MP, Steele JR, Wallace MJ. Safety and Efficacy of an Absorbable Filter in the Inferior Vena Cava to Prevent Pulmonary Embolism in Swine. Radiology. 2017 Dec;285(3):820-829. doi: 10.1148/radiol.2017161880. Epub 2017 Jul 14.
Results Reference
background
PubMed Identifier
27639002
Citation
Dria SJ, Eggers MD. In vitro evaluation of clot capture efficiency of an absorbable vena cava filter. J Vasc Surg Venous Lymphat Disord. 2016 Oct;4(4):472-8. doi: 10.1016/j.jvsv.2016.05.006. Epub 2016 Jul 25.
Results Reference
background
PubMed Identifier
26992619
Citation
Eggers MD, McArthur MJ, Figueira TA, Abdelsalam ME, Dixon KP, Pageon LR, Wallace MJ, Huang SY. Pilot in vivo study of an absorbable polydioxanone vena cava filter. J Vasc Surg Venous Lymphat Disord. 2015 Oct;3(4):409-420. doi: 10.1016/j.jvsv.2015.03.004. Epub 2015 Jun 18.
Results Reference
background
PubMed Identifier
22840802
Citation
Eggers MD, Reitman CA. In vitro analysis of polymer candidates for the development of absorbable vascular filters. J Vasc Interv Radiol. 2012 Aug;23(8):1023-30. doi: 10.1016/j.jvir.2012.05.039.
Results Reference
background

Learn more about this trial

US Pivotal Clinical Study of the Adient Absorbable Filter for the Prevention of Pulmonary Embolism

We'll reach out to this number within 24 hrs